Cor Vasa 2012, 54(3-4):201-203

Cílové hodnoty LDL cholesterolu, varování FDA k léčbě statiny, realita hypolipidemické terapie a kombinační léčba jako možné východisko

Prof. MUDr. Richard Češka, CSc.
Centrum preventivní kardiologie, III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha

Published: March 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češka R. Cílové hodnoty LDL cholesterolu, varování FDA k léčbě statiny, realita hypolipidemické terapie a kombinační léčba jako možné východisko. Cor Vasa. 2012;54(3-4):201-203.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
    2. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Češka R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102[10 Suppl]:1K-34K. Go to original source...
    3. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, et al. Triglyceride - rich lipoproteins and high density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61. Go to original source... Go to PubMed...
    4. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53. Go to original source... Go to PubMed...
    5. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-81. Go to original source... Go to PubMed...
    6. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80. Go to original source... Go to PubMed...
    7. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. Go to original source... Go to PubMed...
    8. Hradec J, Bultas J, Kmínek A, et al. Jak se léčí statiny v České republice? Výsledky průzkumu STEP. Cor Vasa 2011;53:527-34. Go to original source...
    9. Egan A, Coilman E. Weighting of high/dose simvastatin against the risk of myopathy. N Engl J Med 2011;365:285-7. Go to original source... Go to PubMed...
    10. Ballantyne M, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J 2005;149:464-73. Go to original source... Go to PubMed...
    11. Kastelein J. What future for combination therapies? IJCP 2003;134(Suppl):45-50.

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes